×

Fibrocell Science Honored With 2014 Marcum Innovator of the Year Award

EXTON, Pa., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell therapy company focused on developing first-in class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced the company was honored with a 2014 Marcum Innovator of the Year Award. These awards recognize entrepreneurship and innovation by companies in the greater Philadelphia region that are pioneering new advancements in Biotech/Healthcare, Technology, Manufacturing, and Business Services sectors. David Pernock, Chairman and CEO of Fibrocell Science, accepted the award at a ceremony in Philadelphia on Wednesday evening, October 22, 2014.

"We are proud to be recognized for developing innovative cell-based therapies based on our proprietary fibroblast technology. These treatments have the potential to relieve the suffering of those with painful and debilitating skin and connective tissue diseases, such as recessive dystrophic epidermolysis bullosa, a rare, genetic blistering disorder," said Mr. Pernock. "We appreciate the recognition of our commitment to developing treatments for these patients, as well as our support of the Philadelphia business community."

About Marcum Innovator of the Year Awards

The Marcum Innovator of the Year Awards were formed to honor entrepreneurship and innovation in the Greater Philadelphia marketplace. The Awards celebrate those companies that blaze a trail in their fields by constantly seeking new ways to advance their industries. Finalist companies representing the Biotech/Healthcare, Technology, Manufacturing, and Business Services sectors were honored at an awards ceremony and will be profiled in the September/October issue of Philadelphia SmartCEO magazine.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (Nasdaq:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's lead orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). Working in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is genetically modifying autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and connective tissue disorders. Fibrocell is also pursuing medical applications for azficel-T—the Company's proprietary autologous fibroblast technology—for restrictive burn scarring and vocal cord scarring. Both indications are currently in Phase II clinical trials. For additional information, visit www.fibrocellscience.com.

CONTACT: Investor Relations: Susan Noonan S.A. Noonan Communications, LLC (212) 966-3650 susan@sanoonan.comSource:Fibrocell Science, Inc.